Antibody Drug Conjugates: Technologies and Global Markets
The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%.
- An overview of the global market for ADCs as a part of the pharmaceutical industry that is looking for innovative technologies.
- Analyses of global market trends, with data from 2012, 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of key market drivers and challenges.
- Insight into regulatory hurdles and how to meet them, as well as discussion of the drugs (and the companies behind them) that have received approval.
SCOPE OF REPORT
This report is an analytical business tool whose primary purpose is to describe the ADC drug industry.
For the purposes of this report, commercialized ADCs are those drugs that are approved by the U.S. Food and Drug Administration (FDA) as new drugs that are not sold only as monoclonal antibodies (mAbs). The study’s main focus is on legal, prescription-required therapeutic medicines sold in the open market. For this report, the form of an ADC involving an antibody and small-molecule cytotoxin will be viewed as the ADC of today, though acknowledgement is made in this report that ADCs will expand to encompass other forms of small-molecule drugs possibly in nanoparticle size or some other type.
The study also does not cover the following: mAbs that do not contain a linker and cytotoxic agent and, thus, do not constitute an ADC; however, novel ADC technology and novel ADC-related technology will be discussed.
Again, the format of the study is organized around the following topics:
- Major types and applications of ADC drugs.
- Industry structure.
- Market size and segmentation, including breakdown of sales by therapeutic area and geographic area.
- Market drivers.
- Market projections through 2018.
- Observations and conclusions regarding the future of the industry.
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.